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ABSTRACT
The non-psychoactive compound of cannabis, cannabidiol (CBD), has stood out as promising in treating several disease with new mechanisms of action 
and a favorable side effect profile. The aim of the present study was to evaluate what has been published about CBD in the last 2 years (2019/2020) 
about anxiety, depression, panic attack and dementia, as well as side effects presented by this cannabidiol. The material analyzed consists of the 
cannabidiol (CBD) index in PubMed/Medline, and its relationship with metabolic activity, anxiety, depression, and dementia. The data were collected 
between 2019 and 2020, totaling 76 articles. Although most of the studies found are in the form of a review (55.3%), several clinical studies in humans 
have shown promising results with the use of CBD. The treatments for anxiety and stress with CBD were the most evident, corresponding to 37.8% 
of the total studies, as reported in Table 2. The relationship of CBD in metabolic processes as inflammatory markers was the second most evident 
item in Table 2, with 11.1%. Cognitive processes and depression appear in sequence, with 8.9% each. With 70.6% of favorable results in Table 3, CBD 
appears as a promising option in the treatment of anxiety, stress and similar behaviors. Regarding depression, the results were slightly lower. With 
66.6% positive results, depression can also be treated with CBD as an alternative therapy option. We conclude that the findings in this meta-analysis 
need more studies that show us the use of CBD in behavioral pathologies, especially in the long term, and its interaction with other drugs, as well as 
its pharmacodynamics.
Keywords: Cannabidiol, Anxiety, Depression, Panic attack, Dementia.
INTRODUCTION
Cannabis has been used as a medicinal plant for thousands of years in 
Asia [1]. Cannabis was known in the West by William O’Shaughnessy 
in 1838, who described remarkable results in the treatment of some 
diseases, among than epilepsy, rheumatic pain, and others, using this 
plant [2]. Numerous health benefits have been attributed to cannabis 
since its first reported use in 2600 BC in Chinese pharmacopeia [3]. 
The therapeutic potential of compounds derived from these plants 
has driven interest in the last few years [1]. The non-psychoactive 
compound of cannabis, cannabidiol (CBD), has stood out as promising 
in treating ellipsis as an anticonvulsant with new mechanisms of action 
and a favorable side effect profile [4].
There is interest among medical scientists in the gene-regulating 
properties of CBD [5]. Researchers at the California Pacific Medical 
Center have shown that CBD reduces brain cancer and breast cancer 
cell proliferation and metastasis by inhibiting the expression of the 
ID-1 gene. ID-1 expression is implicated in several kinds of aggressive 
cancer [6]. In 2012, Israeli scientists identified more than 1200 
genes affected by CBD: 608 “gene transcripts” were upregulated by 
cannabidiol and 524 were downregulated by cannabidiol [7]. CBD also 
bears investigation in epilepsy and other neuropsychiatric disorders, 
including anxiety, schizophrenia, addiction, and neonatal hypoxic-
ischemic encephalopathy [4]. Various in vitro and in vivo evidence 
also support CBD’s role in degenerative inflammatory diseases [8]. 
CBD had a strong ability to inhibit the production of inflammatory 
cytokines, including interleukin (IL)-1β, IL-6, and interferon-β, in 
lipopolysaccharide-stimulated murine microglial cells [9,10]. On the 
other hand, recent studies have demonstrated that CBD-induced DNA 
damage in human liver cells when evaluated in vitro to administer 
different doses [11]. In this way, we seek to evaluate, through this 
present study, what has been published about CBD in the PubMed/
Medline database in the past 2 years (2019/2020) concerning anxiety, 
depression, panic attack, and dementia, as well as therapeutic dosages, 
results with significant values, side effects, and others reported in the 
studies found. The results found in the present study may serve as a 
basis for further studies, as well as for treatments that require dose 
adjustment concerning CBD.
MATERIALS AND METHODS
The material analyzed consists of journal articles on the cannabidiol 
(CBD) index in PubMed/Medline, seeking this herb’s relationship 
with metabolic activity, anxiety, depression, and dementia. The data 
were collected between 2019 and 2020, totaling 76 articles. The 
article’s search was done through the keywords cannabidiol, anxiety, 
depression, panic attacks, and dementia.
RESULTS
The results were distribuited in Tables 1-4. In Table 1, we observed 
a predominance of review publications with 55,3%, followed the 
publications of clinical study in humans with 22.4%, and animal 
experiments with 17.1%. The significant proportion of 55.3% of reviews 
found in this study demonstrates a tremendous interest of the scientific 
community in recent years on the properties of CBD, their therapeutic 
applications, and the ratio of the dosage to use. However, in this 
present study, we see the presence of CBD as one of the cannabinoids 
supporting agents present in cannabis, being evaluated, in many cases, 
with other cannabinoids, mainly Δ9 tetrahydrocannabinol (THC). When 
searching for the word cannabidiol, there are many systematic reviews 
about CBD, but not all of them report the benefits and side effects of 
CBD alone. Understanding whether CBD is safe for treating psychiatric 
disorders is essential to empower psychiatrists and patients to make 
sound clinical decisions.
The treatments for anxiety and stress with CBD were the most evident in 
this present review. Studies in both humans (22.2%) and animals (15.6%) 
accounted for 37.8% of the total studies observed in vivo evaluations. The 
relationship of CBD in metabolic processes as inflammatory markers, the 
activator of specific nuclear receptors, and protein modulations was the 
Review Article
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second most evident item in this present review, with 11,1%. Cognitive 
processes and depression appear in sequence, with 8.9% both.
The results of the significance values found in this study demonstrated 
a good acceptance in the treatment with CBD regarding anxiety and 
stress. With 70.6% of positive outcomes, CBD appears as a promising 
option in treating anxiety, stress, and similar behaviors. Regarding 
depression, the results were slightly lower. With 66.6% positive results, 
depression can also be treated with CBD as an alternative therapy 
option. In cognition, the process reversed. About 66.6% did not obtain 
significant developments in the observed surveys, demonstrating that 
CBD has better anxiety results than other behavioral methods.
In Table 4, the dosages for CBD administration are incredibly diverse. 
In the study by Shannon et al. (2019), 25 mg of CBD was used in most 
patients. However, if complaints of anxiety and insomnia predominated, 
patients received from 50 mg to up to 75 mg, depending on the case. 
The authors related that patients with a history of ezquisophrenia 
disorder received doses of up to 175 mg a day. In this study, CBD is used 
as a method to prevent or reduce psychiatric drugs.
DISCUSSION
Although most of the reviews presented in this study have shown 
promising results with the use of CBD, some studies have listed the 
possible side effect of using this cannabinoid. Khoury et al. (2019) 
reported, in their review, that after the analysis included six case reports 
and seven trials, comprising 201 subjects, most the study included six 
case reports and seven clinical trials, covering 201 subjects. Most of the 
published studies had several drawbacks and did not reach statistical 
significance reported by Khoury et al. lies published presented several 
drawbacks and did not reach statistical significance, stated the authors. 
The authors also have not found evidence regarding major depressive 
and bipolar disorders, revealing that CBD’s efficacy and safety in 
psychiatry are still scarce [12].
On the other hand, CBD demonstrated satisfactory therapeutic effects 
in patients with Parkinson’s disease (PD) in the review by Crippa et al. 
(2019). Seven preclinical models of PD found using CBD in this study, with 
six studies showing a CBD neuroprotective effect. Crippa et al. related 
that three studies involving CBD and PD also reported: An open study, a 
case series, and a randomized clinical trial (RCT). CBD well-tolerated and 
all three studies reported significant therapeutic effects on non-motor 
symptoms (psychosis, disturbed sleep behavior by rapid eye movements, 
daily activities, and stigma) [13]. However, the authors noted that the 
sample sizes were small, and treatment with CBD was short (up to 6 
weeks). They related that further stated that large-scale RCTs are needed 
to replicate these results and assess the long-term safety of CBD [13].
CBD in psychiatry
The review of Galapai et al. (2019) on the use of CBD in psychiatry 
brought promising results. The authors conducted studies from 1970 
to 2019 on the use of CBD in psychiatry with the keywords “psychiatry,” 
“schizophrenia,” “anxiety,” “depression,” “autism,” “anxiolytic,” 
“antidepressant,” and “antipsychotic” were one by one added to the 
keyword “cannabidiol.” [14]. In this review, articles published in revised 
scientific journals described CBD’s preclinical effects in psychiatric 
use. Clinical studies conducted with patients affected by psychiatric 
illnesses were collected and discussed only cases of healthy individuals 
unaffected by psychiatric conditions included. The authors report 
that this review’s results confirmed the vision of cannabinoids as a 
promising molecule, especially in psychiatry such as schizophrenia, 
Table 1: Publication types
Years 2019 % 2020 % Total %
Review 39 51.3 3 4.0 42 55.3
In vitro 2 2.6 0 0 2 2,6
In vivo animal 12 15.8 1 1.3 13 17.1
In vivo human 14 18.4 3 4.0 17 22.4
Others 1 1.3 1 1.3 2 2.6
Total articles 68 89.4 8 10.6 76 100
Table 3: The results with significance evaluated in human and animal
Significance Evaluated 2019 2019 2020 2020 Total% Total% Ratio
Results Positive Negative Positive Negative Positive Negative p/n
Anxiety and stress 12 4 - 1 70.6 29.4 24/1
Insomnia 1 - - - 100 - 100/1
Depression 2 - - 1 66.6 33,3 2/1
Metabolism 1 1 - - 50 50 1/1
Phobia and panic attack 1 - 1 - 100 - 100/1
Cognition 1 1 - 1 33.3 66.6 1/2
Dementia 1 - - - 100 - 100/1
Autism 1 - - - 100 - 100/1
Pain 2 1 - - 66.6 33.3 2/1
Table 2: Proposal for evaluating the article in vivo treatment with CBD alone or with other cannabinoids
Disease and Synptoms 2019 % 2020 % Total%
H A H A H A H A H A
Anxiety and stress 8 7 20.0 17.5 2 - 40 - 22.2 15.6
Insomnia 2 - 5.0 - - - - - 4.5 -
Depression 1 2 2.5 5.0 1 - 20 - 4.5 4.4
Metabolism 4 1 10.0 2.5 - - - - 8.9 2.2
Phobia and panic attack 1 1 2.5 2.5 - - - - 2.2 2.2
Cognition - 3 7/5 - 1 - 20 - 2.2 6.7
Dementia 1 - 2.5 - - - - - 2.2 -
Psychotic disorders - - - - 1 - 20 - 2.2 -
Autism 1 - 2.5 - - - - - 2.2 -
Post-traumatic stress disorder 2 - 5.0 - - - - - 4.5 -
Pain 2 1 5.0 2.5 - - - 4.5 2.2
Total 22 15 60 30 5 - 100 - 60.1 33.3
*H: Human, A: Animal
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anxiety, depression, and autism [14]. Still on this review, Calapai 
et al. concluded that although CBD has anti-inflammatory properties 
supported by the large number of experiments using experimental 
laboratory models, the evidence of CBD’s therapeutic effects in the 
psychiatric field is restricted to some clinical studies investigating CBD 
in schizophrenic patients and individuals affected by anxiety. CBD has 
demonstrated a positive impact on some markers of neuroplasticity 
antidepressant effects, such as increased levels of brain-derived 
neurotrophic factor, restores impaired neuron proliferation caused 
by chronic stress in animals. CBD has also been shown to have anti-
inflammatory, antioxidant, immunomodulators, and neuroprotectors, 
probably mediated by interaction with the receptor, and activated by a 
peroxisome proliferator stimulation of hippocampal neurogenesis [15]. 
The properties of CBD that reduces inflammation and oxidative stress 
associated with neurotoxicity, without psychoactive effects, make CBD 
a promising herbal medicine in the treatment of psychiatric disorders, 
say the authors [16].
Considering that modern life has been causing anxiety disorders in 
humans, the search for a natural anxiolytic is a fact. There are no 
evidence that popular and available anxiety levels can detect all or 
most types of anxiety disorder in primary care. Some levels, often used 
in research, measure specific types of anxiety, such as trait anxiety, or 
particular aspects of individual anxiety disorders, such as worry, social 
anxiety, and specific fears, whereas other scales aim to measure a 
common characteristic of most, as the general anxiety [17]. Usually, the 
anxiety process is linked to stress and can trigger insomnia, phobias, 
panic attacks, depression, and pain, in some specific cases [17-21]. CBD 
has been an alternative therapy for both disorders of the human psyche 
mentioned above, and with a good response in the articles observed 
in this present review. However, studies showing the central nervous 
system (CNS) by the CBD, also called attention in this current study.
CBD and liver DNA damage
A surprising result in Russo et al. regarding the use of CBD and DNA 
damage and chromosomal aberrations in human cells found in this 
present study [11]. The authors related that CBD and cannabidivarin 
(CBDV) cause the formation of comets (which reflect single and 
double-strand breaks and apurinic sites), oxidation of DNA bases, and 
induction of micronucleus (MN) (which formed because of structural 
and numerical chromosomal aberrations). The results of this study 
with liver enzyme homogenate suggested that drug-metabolizing 
enzymes (in particular, the CYPs that contained in the enzyme mixture) 
increase the genotoxic properties of CBD and CBDV. It documented 
that different CYPs (in specific CYP1A1, 1A2, and 3A4) catalyze the 
formation of CBD’s hydroxyl derivatives, but the mutagenic properties 
of these metabolites have not yet investigated. The most relevant result 
of this investigation is detecting MN induction by CBD and CBDV in low 
physiologically relevant concentrations [11]. The authors still conclude 
that MNi formed as a consequence of chromosomal damage, and it 
documented that increased human lymphocyte rates indicate cancer 
risks.
CBD and cannabinoid and non-cannabinoid receptors
The mechanisms of action of cannabinoids are thought to be mediated 
cannabidiol receptors at the cell surface [22]. Two types of these 
cannabinoid receptors have so far identified, and both are members 
of the superfamily of G-protein-coupled receptors (GPCRs), CB1 and 
CB2 [22,23]. However, studies have shown that cannabidiol also has 
interactions in several other nuclear receptors, especially regarding 
CBD agonist properties in specific receptors, such as the serotonin 
receptor (5HT) and the peroxisome proliferator-activated receptor 
gamma (PPAR-γ) [24,25]. Several genes regulated by PPARs are involved 
in energy homeostasis, lipid uptake and metabolism, insulin sensitivity, 
and other metabolic functions [26]. In 2011, a research team reported 
that PPAR-γ activation degrades amyloid-beta plaque, a key molecule 
in developing Alzheimer’s disease. PPAR-γ is a nuclear receptor of 
the PPAR family that plays a significant regulatory role in energy 
homeostasis and metabolic function in cells [27]. It is one reason why 
cannabidiol, a PPAR-γ agonist, may be a useful remedy for Alzheimer’s 
patients [15]. In serotonergic receptors, the CBD agonist mechanism 
helps in the behavioral part, including anxiety and pain. Repeated 
treatment with a low dose of CBD induces analgesia predominantly 
through activation of transient receptor potential vanilloid type 1, 
reduces anxiety through activation of the 5-HT1A receptor, and rescues 
impaired 5-HT neurotransmission under conditions of neuropathic 
Table 4: Doses used in human studies
Articles Clinical evaluation Dosage/d
Perm J. 2019;23:18-041 Anxiety and sleep 25 mg–175 mg
(Oral form for 12 weeks)
J Altern Complement Med. 2019 Apr;25(4):392-397 Stress disorder 25 mg caps
9 mg spray
(for 8 weeks)




BMC Psychiatry. 2019 Feb 13;19(1):69 Phobia and panic disorder 300 mg
(for 8 weeks)
Front Pharmacol. 2019 Jan 9;9:1521 Autism symptoms 16 mg/Kg
(max 600 mg)
(for 66 days)
J Neurodev Disord. 2019 Aug 2;11(1):16 Behavioral symptoms associated with FXS 50–250 mg gel
(Transdermal form)
(for 12 weeks)
Am J Psychiatry. 2019 Nov 1;176(11):911-922 Anxiety in drug abstinence 400–800 mg 
(3 days consecutive)
Psychopharmacology (Berl). 2020 Jan 8 Anxiety and stress 600 mg
(for 1 week)
J Psychopharmacol. 2020 Feb;34(2):189-196 Parkinson disease 300 mg
(for 2 weeks)
Front Psychol. 2019 Nov 8;10:2466 Anxiety 300 mg
(for 4 weeks)
Isr Med Assoc J. 2019 Nov;21(11):759-760 Dementia 60 mg
(for 1 week)
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pain [24]. However, the control of inflammation occurs through nuclear 
factor-kappa beta (NF-kB), a protein complex that controls DNA 
transcription, cytokine production, and cell survival [28].
The NF-κβ has attracted widespread attention among researchers 
in many fields. The central role in immunological processes and its 
apparent involvement in several diseases have been reported in several 
scientific studies [28]. The NF-κβ pathway has long been considered a 
prototypical pro-inflammatory signaling pathway, primarily based on 
the role of NF-κβ in the expression of pro-inflammatory genes [29]. 
NF-κβ may have decreased metabolic activity through the PPAR-γ. 
The PPAR-γ is ligand-activated receptors with distinct physiological 
functions in regulating lipid and glucose metabolism and inflammatory 
response [30]. PPAR-γ activation allows a coordinated up-regulation of 
numerous fatty acid oxidation (FAO) enzymes, resulting in significant 
PPAR-driven increases in mitochondrial FAO flux [30].
CBD, metabolism, inflammation, and behavior
There is a correlation between the metabolic part and the behavioral 
part concerning the CBD’s mechanisms of action. Thus, the evidence 
from the studies found in this present work support that CBD has 
become a promising alternative regarding the treatment of anxiety, 
stress, depression, and diseases linked to behavioral disorders. In 
addition to CBD acting as an agonist of 5HT receptors, it also protects 
neurons when there are excesses of glutamate release in the CNS 
exhibiting therapeutic potential for various human diseases, including 
chronic neurodegenerative disorders, such as Alzheimer’s and 
Parkinson’s, ischemic stroke, epilepsy, and other convulsive syndromes, 
neuropsychiatric disorders, neuropathic allodynia, and certain types 
of cancer [31]. Medicinal herbs have been increasingly studied as a 
neuroprotective agent in this 21st century. Research has shown that 
natural herbs are increasingly on a promising path in the treatment of 
neurodegenerative diseases [32]. Although Roy and Awasthi (2017) 
mentioned several medicinal herbs with promising results, they did not 
say cannabidiol as an asset in their studies.
On the other hand, Rodrigues-Munhoz (2019) affirmed that CBD 
exhibits positive effects in situations in which glutamatergic signaling, 
mainly that mediated by N-methyl-D-aspartate acid receptor 
(NMDAR), plays a critical role. A recent study has revealed that the 
sigma-1 receptor (σ1R) antagonism prevents GPCRs from enhancing 
the function of NMDARs, thereby reducing the cellular impact of the 
excessive glutamatergic activity. CBD interacts as an σ1R antagonist. 
This demonstrated that CBD exhibits antioxidant properties and 
protects neurons from glutamate-induced death without cannabinoid 
receptor activation or NMDAR antagonism [31].
Another exciting factor about CBD regarding behavior is its interaction 
with an autism spectrum disorder. A recent study with CBD in autistic 
children showed a significant improvement in the patients using 
CBD [33]. This study supported the feasibility of CBD testing in children 
with autism. On the other hand, despite the growing interest in CBD as 
monotherapy or complementary treatment for the main symptoms and 
comorbidities of ASD [34], there are currently no convincing preclinical 
or clinical data to demonstrated the efficacy and safety of cannabinoid 
treatment in patients with ADS.
On the other hand, we observed a crucial neuroprotection mechanism 
associated with CBD in the main oxidative stress control enzyme, 
superoxide dismutase (SOD) [35]. The upregulation of the mRNA 
levels mediates the mechanism of neuroprotection and anti-
inflammatory exerted by CBD for Cu–Zn SOD, an essential enzyme in 
endogenous defenses against oxidative stress, mainly in the production 
of superoxide (O-) due to cellular respiration [35]. This enzyme 
interacts in controlling the reactive oxygen species (ROS) produced 
in the mitochondria in the respiratory chain. ROS production triggers 
damage to DNA, RNA, and proteins in cells [36]. Thus, CBD’s control of 
SOD expression may offer a promising future not only in the control of 
oxidative stress but also in inflammation. In a review of arthritis and 
medicinal plants, Paul et al. (2015) reported that cannabinoids act 
as potent immunosuppressive and anti-inflammatory agents in their 
respective CB1 and CB2 receptors and measure the beneficial effects in 
a wide range of immune-mediated diseases, such as multiple sclerosis, 
diabetes, septic shock, rheumatoid arthritis, and allergic asthma [37]. 
This review corroborates with other results found in this present study 
on the positive effects of cannabinoids on use in anti-inflammatory 
therapies.
CBD, anxiety, and sleep
In comparing the positive and negative results concerning anxiety, 
we can observe some differences between the studies. Shannon et al. 
(2019) related an interesting retrospective case series at a psychiatric 
clinic involving CBD’s clinical application in both anxiety and sleep 
complaints as an adjunct to usual treatment. This retrospective chart 
review included monthly documentation of anxiety and sleep quality 
in 103 adult patients. In this study, the average age for patients with 
anxiety was 34 years (range = 18–70 years) and age 36.5 years for 
patients with sleep disorders (range = 18–72 years). Most patients with 
an anxiety diagnosis were men (59.6%, 28/47), whereas more sleep-
disordered patients were women (64.0%, 16/25) [38]. The authors 
related that all 72 patients completed sleep and anxiety assessments 
at the onset of CBD treatment and at the 1st monthly follow-up. By 
the 2nd monthly follow-up, 41 patients (56.9%) remained on CBD 
treatment and completed assessments; 27 patients (37.5%) remained 
on CBD treatment at the 3rd monthly assessment. On average, anxiety 
and sleep improved for most patients, which sustained overtime [38]. 
Still the same study, at the 1st monthly assessment after the start of 
CBD treatment, 79.2% (57/72) and 66.7% (48/72) of all patients 
experienced an improvement in anxiety and sleep, respectively; 15.3% 
(11/72) and 25.0% (18/72) experienced worsening symptoms in stress 
and rest, respectively. Two months after the start of CBD treatment, 
78.1% (32/41) and 56.1% (23/41) of patients reported improvement 
in anxiety and sleep, respectively, compared with the prior monthly 
visit; again, 19.5% (8/41) and 26.8% (11/41), respectively, reported 
worsening problems as compared with the preceding month, related 
the authors. The results of Shannon et al. (2019) demonstrated a more 
sustained response to anxiety than for sleepover time. Patient records 
displayed a more considerable decrease in anxiety scores than in sleep 
scores. The sleep scores demonstrated mild improvement. The anxiety 
scores decreased within the 1st month and then remained reduced 
during the study duration [38].
Similarly, Masataka proposed to investigate the possible effectiveness of 
CBD as at least an adjunct option for intervention in people with a social 
anxiety disorder (SAD) [39]. The author sought to systematically assess 
CBD’s effectiveness in a total of 37 Japanese from 18 to 19 years of age 
with SAD, all naive to any form of treatment, measuring the level of SAD 
symptoms with both groups. The Negative Assessment Fear Questionnaire 
(FNE; Watson and Friend, 1969) and the Liebowitz Social Anxiety Scale 
(LSAS; Liebowitz, 1987) using a parallel, double-blind, experimental, 
exploratory, experimental paradigm. The results of this study provided 
evidence of the anxiolytic effects of repeated administration of CBD in 
adolescents with SAD. At the same time, however, the author recognizes 
several limitations of the present study. No CBD blood level test has 
been performed. According to the authors, a more detailed baseline 
sociodemographic assessment could have carried out to guarantee the 
pre-treatment similarity of the treatment groups [39]. They further 
stated that measurements need to take at additional times between the 
baseline and the end of the study. Such measures would be essential to 
show, for example, whether CBD could produce a rapid improvement in 
social anxiety (a putative advantage over paroxetine). Besides, possible 
side effects should be assessed systematically [39]. According to the 
authors, these are questions for future research that should also be long-
term studies with the positive control (for example, paroxetine) to assess 
the potential usefulness of CBD in SAD therapy.
Interestingly, in a study by Linares et al. (2019), CBD was used to 
compare the acute effects of different doses of CBD itself and placebo 
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in healthy volunteers who perform a simulated public speaking test, a 
well-tested method anxiety induction. The authors used a total of 57 
healthy male subjects who were prepared to receive oral CBD at doses 
of 150 mg (n=15), 300 mg (n=15), 600 mg (n=12) or placebo (n=15) in 
a double dose blind procedure. The results showed that pre-treatment 
with 300 mg of CBD significantly reduced anxiety during speech 
compared to placebo. No significant differences were observed in the 
Visual Analog Mood Scale [40].
Interestingly, in the study by Schleicher et al. (2019), CBD’s behavioral 
profile was investigated with a battery of behavioral tests, including 
motor, anxiety, and memory tests after prolonged CBD treatment. Adult 
C57Bl/6J wild-type (WT) mice were daily intraperitoneally injected 
with 20 mg/kg CBD for 6 weeks starting at two different points of ages 
(3 months and 5 months) to compare the influence of prolonged CBD 
treatment with a washout period (former group) to the effects of long-
term CBD treatment (current group) [41]. The results of this study 
showed that CBD treatment does not influence motor performance on 
an accelerating rotarod test, while it also results in a lower locomotor 
activity in the open field (OF). No CBD influence on spatial learning and 
long-term memory in the Morris water maze was observed. Memory in 
the novel object recognition test was unaffected by CBD treatment [41]. 
Two different anxiety tests revealed that CBD does not affect anxiety 
behavior in the dark-light box and OF test. However, anxiety is altered 
by current CBD treatment in the elevated plus maze.
Moreover, according to the authors, CBD-treated C57Bl/6J mice showed 
an unaltered acoustic startle response compared to vehicle-treated 
mice. However, current CBD treatment impairs pre-pulse inhibition 
(PPI), a test to analyze sensorimotor gating. The authors conclude 
that prolonged CBD treatment did not affect the hippocampal neuron 
number, and the results demonstrate that protracted CBD treatment 
has no adverse effect on the behavior of adult C57Bl/6J mice [41].
In a study by Appiah-Kusi (2019), the authors investigated CBD’s 
effects on neuroendocrine responses to stress anxiety in high-risk 
clinical patients for patients with psychosis (CHR). Thirty-two CHR 
patients and 26 healthy controls (HC) took part in the trier social 
stress test, and their serum cortisol, anxiety, and stress associated 
with public speaking were estimated [42]. Half of the CHR participants 
were on 600 mg/day of CBD (CHR-CBD), and half were on placebo 
(CHR-P) for 1 week. The results of this study showed that a one-way 
analysis of variance (ANOVA) revealed a significant effect of group 
(HC, CHR-P, and CHR-CBD) (p=0.005) on cortisol reactivity as well as 
a significant (p=0 .003) linear decrease [40]. According to the authors, 
the change in cortisol associated with experimental stress exposure 
was most notable in HC controls and least in CHR-P patients, with CHR-
CBD patients exhibiting an intermediate response. Planned contrasts 
revealed that the cortisol reactivity was significantly different in HC 
compared with CHR-P (p=0.003) and in HC compared with CHR-CBD 
(p=0.014) but was not different between CHR-P and CHR-CBD (p=0.70) 
[42]. The related Thar across the participant groups (CHR-P, CHR-CBD, 
and HC), changes in anxiety, and experience of public speaking stress 
(all p’s<0.02) were most significant in the CHR-P and least in the HC, 
with CHR-CBD participants demonstrating an intermediate level of 
change. Through the results obtained, the authors concluded that it is 
worth designing more successful studies that investigate whether CBD 
can be used to affect the response to cortisol at high clinical risk for 
patients with psychosis and any effect that this may have on symptoms 
[42].
Although the studies in this review have shown promising results 
regarding CBD’s use in the behavioral part, more studies are needed 
to adjust doses, treatment time, and side effects, especially with long-
term use. We have not had a longitudinal study using CBD to measure 
its benefits and possible adverse effects, only short-term studies. As 
the variety of papers published in this review is very heterogeneous, 
it is challenging to measure CBD safety, therapeutic doses, and drug 
interactions when used with other drugs. CBD is metabolized by 
cytochrome P450 (CYP450) [43], an enzyme that also participates 
in several other drug’ metabolization. Therefore, much attention is 
needed when prescribing CBD with another medication to interact 
in the metabolization process. Most of the studies, by the way, place 
CBD as a therapeutic potential in behavioral treatments, such as 
anxiety, phobias, and pain. However, none of them safely points out 
the pharmacodynamics of this cannabinoid. There have been several 
studies where CBD has used with other cannabinoids, mainly THC, 
showing that both alone and other cannabinoids, the effects were most 
promising. However, at this moment, there is a need for further future 
studies to point out the anxiolytic potential of CBD.
CBD dosage
Therefore, the selection and dosage of CBD reflected the clinical 
preference individually [37]. Informed consent was obtained for each 
patient treated and considered for this study. Monthly visits included 
clinical assessment and documentation of patients’ anxiety and sleep 
status using validated measures, said the authors. Still, in the same study, 
the authors related that CBD was added to the treatment, removed from 
the treatment, or refused according to the patient and the professional’s 
individual preference, and it was used as a method to prevent or reduce 
psychiatric drugs. Therefore, the selection and dosage of CBD reflected 
the clinical preference individually. Informed consent was obtained 
for each patient treated and considered for this study [38]. Monthly 
visits included clinical assessment and documentation of patients’ 
anxiety and sleep status using validated measures. CBD was added to 
the treatment, removed from the treatment, or refused according to 
the patient and the professional’s individual preference. Therefore, the 
study of Shannon et al. (2019) was unable to provide us with a dosage 
standard since the doses were adequate individually and did not 
respect a sample for evaluation.
When comparing the studies presented in this table, we can observe 
that despite the difficulty of finding a dosage in the use of CBD, the 
versatility in the use of this cannabinoid is remarkable. In the study 
by Linares et al. (2019), patients received much higher doses of 
CBD to treat anxiety when these patients needed to speak in public 
in comparison of the study by Shannon et al. These doses were 
chosen based on previous evidence that acute anxiolytic effects 
have observed in healthy subjects given amounts ranging from 300 
to 600 mg of CBD [40]. According to Shannon et al., the doses used 
in his study (25 mg/d to 175 mg/d) were much lower than those 
reported in some of the clinical literature, such as the Linares et al. 
study (300 mg/d to 600 mg/d). The authors attributed this to two 
distinct factors. First, lower doses seem to cause an adequate clinical 
response. Second, CBD’s current retail cost would make the use of 
600 mg/d prohibitive [40].
Interestingly, two other studies observed in the table above, 
Appiah-Kusi et al. and Masataka, treated their respective patients with 
dosages of 600 mg and 300 mg, respectively [39,42]. Appia-Kusi et al. 
used doses of 600 mg to treat patients with a high degree of anxiety, 
checking whether CBD would normalize neuroendocrine and stress 
anxiety responses in high-risk clinical patients for psychosis (CHR). At 
the same time, Masataka treated 37 young people with SAD with 300 
mg of CBD a day. According to this author, in his study, it was reported 
that the previous studies showed that CBD reduces anticipatory 
anxiety, such as speaking in public, for example. Moreover, CBD was 
found to exert a significant effect on increased brain activity in the 
right posterior cingulated cortex that thought to be involved in the 
processing of emotional information [39].
Even higher doses of CBD were found in the study by Hurd et al. (2019). 
These authors investigated CBD’s potential to reduce stimulus-induced 
desire and anxiety, two critical characteristics of addiction that often 
contribute to relapse and continued drug use in individuals abstaining 
from drugs with heroin use disorder [43,44]. As we can see, this 
treatment cannot be compared to the others due to the characteristics 
of patients abstaining from drugs with a disorder caused by heroin 
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use. These are different cases from those used in the table above and 
have different needs about the doses used and the time used. Acute 
CBD administration, in contrast to placebo, significantly reduced both 
craving and anxiety induced by the presentation of salient drug cues 
compared with neutral signals [44]. CBD also showed significant 
prolonged effects on these test 7 days after the final short-term (3-day) 
CBD exposure. Besides, Hurd et al. (2019) related that CBD reduced 
the drug cue-induced physiological measures of heart rate and salivary 
cortisol levels.
CONCLUSION
Analyzing the work in this review, we concluded that CBD is still a 
new asset in phytochemicals. Since its dosage, proposed treatment, 
side effects, contraindications, and mainly its pharmacodynamics, we 
are still in need of studies that show us the use of CBD in behavioral 
pathologies, primarily in the long term and its interaction with other 
drugs. Although all the results presented in this study are promising, 
we need more information to position ourselves on the efficiency of 
CBD in proposed treatments. A fact observed in earlier studies on CBD 
was the difference observed in the therapeutic curve concerning the 
isolated CBD and the full spectrum CBD, where the full spectrum tends 
to maintain the therapeutic effect for an indefinite period of use, while 
the isolate loses its action in continuous use.
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